Drugs / UX016
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07511556 | Oct 2026 → Dec 2028 expected | myopathy | Ultragenyx Pharmaceutical Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UX016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07511556 ↗ |
| Known as | Sialic Acid-C16 Prodrug | “A Phase 1/2, First-in-human, Double-blind, Placebo-controlled Study to Assess Dose, Safety, and Efficacy of UX016 (Sialic Acid-C16 Prodrug) in Adults With GNE Myopathy” NCT07511556 ↗ |
| Route | Oral | “Tablets for oral use” NCT07511556 ↗ |